Les petites molécules dans la rectocolite hémorragique en 2026 (notice n° 2079605)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 03285cam a2200277 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20260405004933.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Le Cosquer, Guillaume |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | Les petites molécules dans la rectocolite hémorragique en 2026 |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2026.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 19 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Au cours de la dernière décennie, le développement de nouvelles petites molécules (composés organiques de faible poids moléculaire, synthétisés chimiquement et administrés par voie orale) a considérablement élargi l’arsenal thérapeutique de la rectocolite hémorragique (RCH). Trois petites molécules ciblant la voie des Janus kinases (JAK) (tofacitinib, upadacitinib et filgotinib), ainsi qu’une molécule modulant la voie des récepteurs de la sphingosine-1-phosphate (S1PR), l’étrasimod, ont démontré leur efficacité tant pour l’induction que pour le maintien de la rémission. En raison du caractère pléiotropique des voies de signalisation ciblées, ces traitements se distinguent des biothérapies par des profils de tolérance, des risques spécifiques et des contre-indications particulières, nécessitant une évaluation rigoureuse du rapport bénéfices/risques. Cette mini-revue a pour objectif de synthétiser les données d’efficacité et de tolérance issues des programmes de développement clinique des petites molécules dans la RCH. Enfin, nous discuterons des données récemment disponibles concernant l’obéfazimod, un modulateur de l’expression des micro-ARN (miRNA), dont les résultats positifs des études de phase III ont été communiqués en 2025. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Over the past decade, the development of new small molecules (low molecular weight organic compounds chemically synthesized and administered orally) has significantly expanded the therapeutic armamentarium for ulcerative colitis (UC). Three small molecules targeting the Janus kinase (JAK) pathway (tofacitinib, upadacitinib, and filgotinib), as well as one modulator of the sphingosine-1-phosphate receptors (S1PR) receptor pathway (etrasimod) have demonstrated efficacy for both induction and maintenance of remission. Given the pleiotropic nature of the signaling pathways targeted by these agents, small molecules exhibit safety profiles, specific risks, and contraindications that differ from those of biologics, warranting careful assessment of the benefits/risks balance. This mini-review aims to summarize the efficacy and safety data derived from the clinical development programs of small molecules in ulcerative colitis. Finally, we will discuss the available data on obefazimod, a modulator of microRNA expression, for which positive phase III trial results were reported in 2025. |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | anti JAK |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | modulateurs de S1PR |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | petites molécules |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | rectocolite hémorragique |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | JAK inhibitors |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | S1PR modulators |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | small molecules |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | ulcerative colitis |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Gilletta, Cyrielle |
| Relator term | author |
| 786 0# - DATA SOURCE ENTRY | |
| Note | Hépato-Gastro & Oncologie Digestive | - | N° Supp 2 | 2026-03-26 | p. 7-19 | 2115-3310 |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://stm.cairn.info/revue-hepato-gastro-oncologie-digestive-2026-hs2-page-7?lang=fr&redirect-ssocas=7080">https://stm.cairn.info/revue-hepato-gastro-oncologie-digestive-2026-hs2-page-7?lang=fr&redirect-ssocas=7080</a> |
Pas d'exemplaire disponible.
Réseaux sociaux